Genefit (GNFTF) 34.6080 $GNFTF
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 279.25 (+7.48)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 10.58 (-0.10), GILD: 101.77 (+0.61), CNAT: 6.08 (-0.02), ICPT: 279.25 (+7.48)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 279.25 (+7.48)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 279.25 (+7.48), TWTR: 51.94 (-0.23)
Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
at The Street - Fri Mar 27, 8:40AM CDT
The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
ICPT: 279.25 (+7.48)
Intercept up on Genfit's data-messaging presentation of NASH data
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:21PM CDT
ICPT: 279.25 (+7.48)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 102.06 (+0.73), GTXI: 0.71 (+0.04), ESPR: 100.86 (+0.72), ISIS: 65.70 (+1.64), PFE: 35.44 (+0.41), NEOT: 8.14 (+0.27), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin
at The Street - Fri Mar 13, 8:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
AMRN: 2.59 (unch), ICPT: 279.25 (+7.48), CUR: 1.94 (+0.07)
Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT
GLMD: 9.69 (+0.59), RPTP: 10.58 (-0.10), GILD: 101.77 (+0.61), LJPC: 17.87 (+0.12), CNAT: 6.08 (-0.02), SHPG: 248.77 (-5.55), MRK: 57.25 (-0.18), GALT: 3.26 (+0.02), ICPT: 279.25 (+7.48), RGDO: 1.19 (-0.02)
Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.
at The Street - Wed Mar 11, 8:58AM CDT
It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.
ICPT: 279.25 (+7.48)
Genfit: Pivotal Phase IIb Data On NASH Offers High Risk/Reward Trade
Arthur Jeannerot - at Seeking Alpha - Sat Mar 07, 6:37AM CST
SAN: 7.32 (-0.07), GILD: 101.77 (+0.61), ICPT: 279.25 (+7.48), SNY: 52.35 (+0.48)
Insulin Resistance Therapeutics Pipeline Review 2015 - 10 Companies & 20 Drug Profiles
M2 - Tue Mar 03, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ptjz4f/insulin) has announced the addition of the "Insulin Resistance - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AUS Bio Limited - Genfit SA - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Mertiva AB - Mochida Pharmaceutical Co., Ltd. - Novartis AG - Prometheon Pharma, LLC - Sanofi - Thetis Pharmaceuticals LLC Drug Profiles - 6860766 - Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - BVS-857 - Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Englerin A - GFT-505 - MD-960 - Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - PEG-Catalase - Peptide for Obesity and Insulin Resistance - SAR-088 - SERX-1 - Small Molecule for Hypertension and Insulin Resistance - Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders - Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - TP-113 For more information visit http://www.researchandmarkets.com/research/ptjz4f/insulin
GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 22.61 (+0.19), CBSTZ: 0.06 (unch), CNAT: 6.08 (-0.02), GALT: 3.26 (+0.02), NVO: 55.94 (+1.34), RPTP: 10.58 (-0.10), ISIS: 65.70 (+1.64), GILD: 101.77 (+0.61), SHPG: 248.77 (-5.55), ICPT: 279.25 (+7.48), TBRA: ()
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 35.44 (+0.41), AMGN: 163.38 (+1.89), GSK: 48.23 (+0.51), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), CBAY: 6.28 (-0.07), NVS: 103.58 (+1.01)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 207.50 (+1.78), SLXP: 172.96 (+0.15), ICPT: 279.25 (+7.48), SPPI: 6.00 (+0.08), EXAS: 22.76 (-0.10)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 9.69 (+0.59), RPTP: 10.58 (-0.10), GILD: 101.77 (+0.61), LJPC: 17.87 (+0.12), CNAT: 6.08 (-0.02), GALT: 3.26 (+0.02), ICPT: 279.25 (+7.48)
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 35.44 (+0.41), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), CBAY: 6.28 (-0.07), NVS: 103.58 (+1.01)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 10.58 (-0.10), RGDO: 1.19 (-0.02)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 55.94 (+1.34), RPTP: 10.58 (-0.10), ISIS: 65.70 (+1.64), GILD: 101.77 (+0.61), GALT: 3.26 (+0.02), ICPT: 279.25 (+7.48), TBRA: ()
The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 7:28AM CST
GILD: 101.77 (+0.61)
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 279.25 (+7.48)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 10.58 (-0.10), GILD: 101.77 (+0.61), CNAT: 6.08 (-0.02), ICPT: 279.25 (+7.48)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 279.25 (+7.48)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 279.25 (+7.48), TWTR: 51.94 (-0.23)
Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
at The Street - Fri Mar 27, 8:40AM CDT
The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
ICPT: 279.25 (+7.48)
Intercept up on Genfit's data-messaging presentation of NASH data
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:21PM CDT
ICPT: 279.25 (+7.48)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 102.06 (+0.73), GTXI: 0.71 (+0.04), ESPR: 100.86 (+0.72), ISIS: 65.70 (+1.64), PFE: 35.44 (+0.41), NEOT: 8.14 (+0.27), AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56), GSK: 48.23 (+0.51)
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin
at The Street - Fri Mar 13, 8:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
AMRN: 2.59 (unch), ICPT: 279.25 (+7.48), CUR: 1.94 (+0.07)
Differences in NASH studies make direct comparisons a bit tricky
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:56AM CDT
GLMD: 9.69 (+0.59), RPTP: 10.58 (-0.10), GILD: 101.77 (+0.61), LJPC: 17.87 (+0.12), CNAT: 6.08 (-0.02), SHPG: 248.77 (-5.55), MRK: 57.25 (-0.18), GALT: 3.26 (+0.02), ICPT: 279.25 (+7.48), RGDO: 1.19 (-0.02)
Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.
at The Street - Wed Mar 11, 8:58AM CDT
It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.
ICPT: 279.25 (+7.48)
Genfit: Pivotal Phase IIb Data On NASH Offers High Risk/Reward Trade
Arthur Jeannerot - at Seeking Alpha - Sat Mar 07, 6:37AM CST
SAN: 7.32 (-0.07), GILD: 101.77 (+0.61), ICPT: 279.25 (+7.48), SNY: 52.35 (+0.48)
Insulin Resistance Therapeutics Pipeline Review 2015 - 10 Companies & 20 Drug Profiles
M2 - Tue Mar 03, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ptjz4f/insulin) has announced the addition of the "Insulin Resistance - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AUS Bio Limited - Genfit SA - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Mertiva AB - Mochida Pharmaceutical Co., Ltd. - Novartis AG - Prometheon Pharma, LLC - Sanofi - Thetis Pharmaceuticals LLC Drug Profiles - 6860766 - Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - BVS-857 - Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Englerin A - GFT-505 - MD-960 - Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - PEG-Catalase - Peptide for Obesity and Insulin Resistance - SAR-088 - SERX-1 - Small Molecule for Hypertension and Insulin Resistance - Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders - Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - TP-113 For more information visit http://www.researchandmarkets.com/research/ptjz4f/insulin
GSK: 48.23 (+0.51), NVS: 103.58 (+1.01)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 22.61 (+0.19), CBSTZ: 0.06 (unch), CNAT: 6.08 (-0.02), GALT: 3.26 (+0.02), NVO: 55.94 (+1.34), RPTP: 10.58 (-0.10), ISIS: 65.70 (+1.64), GILD: 101.77 (+0.61), SHPG: 248.77 (-5.55), ICPT: 279.25 (+7.48), TBRA: ()
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 35.44 (+0.41), AMGN: 163.38 (+1.89), GSK: 48.23 (+0.51), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), CBAY: 6.28 (-0.07), NVS: 103.58 (+1.01)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 207.50 (+1.78), SLXP: 172.96 (+0.15), ICPT: 279.25 (+7.48), SPPI: 6.00 (+0.08), EXAS: 22.76 (-0.10)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 9.69 (+0.59), RPTP: 10.58 (-0.10), GILD: 101.77 (+0.61), LJPC: 17.87 (+0.12), CNAT: 6.08 (-0.02), GALT: 3.26 (+0.02), ICPT: 279.25 (+7.48)
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 35.44 (+0.41), MRK: 57.25 (-0.18), AZN: 69.91 (-0.25), CBAY: 6.28 (-0.07), NVS: 103.58 (+1.01)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 10.58 (-0.10), RGDO: 1.19 (-0.02)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 55.94 (+1.34), RPTP: 10.58 (-0.10), ISIS: 65.70 (+1.64), GILD: 101.77 (+0.61), GALT: 3.26 (+0.02), ICPT: 279.25 (+7.48), TBRA: ()
The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 7:28AM CST
GILD: 101.77 (+0.61)
